tiprankstipranks
Nuformix Plc (GB:NFX)
LSE:NFX

Nuformix Plc (NFX) Price & Analysis

Compare
6 Followers

NFX Stock Chart & Stats


---

Financials

Quarterly

Options Prices

Currently, No data available
---

Ownership Overview

5.63%94.37%
― Other Institutional Investors
94.37% Public Companies and
Individual Investors

NFX FAQ

What was Nuformix Plc’s price range in the past 12 months?
Nuformix Plc lowest share price was 0.04p and its highest was 0.30p in the past 12 months.
    What is Nuformix Plc’s market cap?
    Nuformix Plc’s market cap is £1.35M.
      When is Nuformix Plc’s upcoming earnings report date?
      Nuformix Plc’s upcoming earnings report date is Dec 16, 2025 which is in 296 days.
        How were Nuformix Plc’s earnings last quarter?
        Nuformix Plc released its earnings results on Jan 29, 2025. The company reported -0.004p earnings per share for the quarter, missing the consensus estimate of N/A by -0.004p.
          Is Nuformix Plc overvalued?
          According to Wall Street analysts Nuformix Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Nuformix Plc pay dividends?
            Nuformix Plc does not currently pay dividends.
            What is Nuformix Plc’s EPS estimate?
            Nuformix Plc’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Nuformix Plc have?
            Nuformix Plc has 1,669,309,300 shares outstanding.
              What happened to Nuformix Plc’s price movement after its last earnings report?
              Nuformix Plc reported an EPS of -0.004p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -42.857%.
                Which hedge fund is a major shareholder of Nuformix Plc?
                Currently, no hedge funds are holding shares in GB:NFX
                ---

                Company Description

                Nuformix Plc

                Nuformix PLC is a pharmaceutical development company. It is focused on building value for shareholders through its activities in drug development and by out-licensing. The company uses cocrystal technology to re-engineer the crystalline form of known small molecule drugs. Its pipeline products include NXP001, NXP002, and NXP004.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Futura Medical
                Oilex Ltd
                Sareum Holdings
                Scancell Holdings
                ValiRx plc
                Popular Stocks
                ---
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis